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Background:   Liver dysfunction increases post-surgical morbidity and mortality. MELD-XI has been evaluated in ambulatory heart failure 
patients and in those receiving VAD support in a single center. Use of MELD-XI in a pediatric post-HT population has not been previously 
reported.
methods:  5711 HT recipients were identified from UNOS (1987-2011) and stratified by MELD-XI score ≥ 17 (n=1918) or < 17 (n=3793) 
calculated using creatinine and bilirubin at time of transplant. Exclusions: age<18, re-HT & lost to follow up, missing creatinine and bilirubin. 
Survival was censored at 12y. Multivariate Cox proportional hazard regression analysis was adjusted for age, sex, DM, race, ischemic time, 
dialysis, life support, VAD use, wait time & HLA mismatch.
results:  MELD-XI ≥ 17 was associated with younger age (p<0.001), less prior cardiac surgery (p<0.001), younger donor age (p<0.001), 
less VAD use (p<0.001) and increased ventilator use (p<0.001) with a shorter wait time (p<0.001). MELD-XI ≥17 were more likely to be 
listed as status 2 (30% vs 24%, p<0.001). Survival (1, 5 & 10y) was: MELD-XI < 17 (88, 73, 59%) & MELD-XI ≥17 (76, 61, 48%) (Figure). 
Unadjusted HR (compared to MELD-XI < 17) for all-cause mortality was 1.51 (CI 1.39-1.66). Multivariate analysis yielded a HR of 1.53 (CI 
1.37-1.70).
conclusion:  Survival is significantly reduced post-HT in patients with MELD-XI ≥17. Prospective study is warranted as MELD-XI may 
provide insight into patient selection in the pediatric population.
  
